Astragalus membranaceus up-regulate Cosmc expression and reverse IgA dys-glycosylation in IgA nephropathy

BMC Complementary and Alternative Medicine

Research Article

Wanxing Tang¹  Lichuan Yang¹  Ling Ji¹  Zi Li¹  XiaoLei Chen¹  Wei Qin¹  Junming Fan²  Xiang Zhong³ 

[1] Division of Nephrology, Department of Medicine, West China Hospital of Sichuan University, 37 # Guoxue road, Wuhou District, Chengdu, Sichuan, China;Division of Nephrology, Department of Medicine, West China Hospital of Sichuan University, 37 # Guoxue road, Wuhou District, Chengdu, Sichuan, China;State Key Laboratory of Biotherapy of Sichuan University, Chengdu, Sichuan, China;Division of Nephrology, Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China;

关键词: IgA nephropathy;    Astragalus membranaceus;    Cosmc;    Glycosylation;   

DOI  :  10.1186/1472-6882-14-195

 received in 2013-05-27, accepted in 2014-06-12,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundDecreased Core I β3-Gal-T-specific molecular chaperone (Cosmc) expression induced IgA1 aberrant glycosylation is the main characteristic of IgA nephropathy (IgAN). This study tried to elucidate the effect of Astragalus membranaceus on Cosmc expression and IgA O-glycosylation of peripheral B lymphocytes in IgAN patients.MethodsPeripheral B lymphocytes of 21 IgAN patients and 10 normal controls were isolated and cultured with or without lipopolysaccharide (LPS) and Astragalus membranaceus injection (AMI). Cosmc mRNA and protein expression levels were measured by real-time RT-PCR and Western blot. IgA1 and glycosylation level were determined by enzyme-linked immunosorbent assay (ELISA) and VV lectin-binding method.ResultsCosmc mRNA expression and IgA1 O-glycosylation level in IgAN patients was significantly lower than normal controls at baseline. Treatment of LPS could obviously inhibit Cosmc expression and increase the IgA1 secretion in peripheral B lymphocytes of IgAN patients, which resulted in a significantly increase in IgA1 aberrant glycosylation level. Addition of AMI could remarkably up regulated Cosmc expression, decrease IgA1 secretion, and reverse glycosylation level in a dose related manner.ConclusionAMI can up-regulate Cosmc expression of peripheral B lymphocytes and reverse IgA1 aberrant O-glycosylation level, which might be the underlying mechanism of AMI therapy in treating IgAN.Trial registrationTCTR20140515001 (Registration Date: 2014-05-15)

【 授权许可】

Unknown   
© Ji et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.